Title: High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver
transplantation and the role of controlled attenuation parameter
Version: 2 Date: 16 Aug 2023
Reviewer's report:
Dear authors
In this study, Mak et al address that High prevalence of de novo metabolic dysfunction-
associated fatty liver disease after liver transplantation and the role of controlled attenuation
parameter. Although NAFLD remains an uncommon primary liver disease indication for LT
in Chinese patients, post-transplant de novo graft steatosis is common and the majority is
classified as MAFLD. Development of graft steatosis is not associated with an increase in graft
fibrosis but was associated with worse metabolic control and graft dysfunction. Routine CAP
measurement to detect de novo graft steatosis should be considered after LT regardless of the
primary indication of LT.
The authors have point-by-point responses to the editorial and reviewer comments and the
revisions are well response to editorial and reviewer comments. The article is well-written and
considered to publish in the BMC Gastroenterology.
Title: High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver
transplantation and the role of controlled attenuation parameter
Version: 2 Date: 16 Aug 2023
Reviewer's report:
Dear authors
In this study, Mak et al address that High prevalence of de novo metabolic dysfunction-
associated fatty liver disease after liver transplantation and the role of controlled attenuation
parameter. Although NAFLD remains an uncommon primary liver disease indication for LT
in Chinese patients, post-transplant de novo graft steatosis is common and the majority is
classified as MAFLD. Development of graft steatosis is not associated with an increase in graft
fibrosis but was associated with worse metabolic control and graft dysfunction. Routine CAP
measurement to detect de novo graft steatosis should be considered after LT regardless of the
primary indication of LT.
The authors have point-by-point responses to the editorial and reviewer comments and the
revisions are well response to editorial and reviewer comments. The article is well-written and
considered to publish in the BMC Gastroenterology.
Please review this paper.
user
Title: High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver
transplantation and the role of controlled attenuation parameter
Version: 2 Date: 16 Aug 2023
Reviewer's report:
Dear authors
In this study, Mak et al address that High prevalence of de novo metabolic dysfunction-
associated fatty liver disease after liver transplantation and the role of controlled attenuation
parameter. Although NAFLD remains an uncommon primary liver disease indication for LT
in Chinese patients, post-transplant de novo graft steatosis is common and the majority is
classified as MAFLD. Development of graft steatosis is not associated with an increase in graft
fibrosis but was associated with worse metabolic control and graft dysfunction. Routine CAP
measurement to detect de novo graft steatosis should be considered after LT regardless of the
primary indication of LT.
The authors have point-by-point responses to the editorial and reviewer comments and the
revisions are well response to editorial and reviewer comments. The article is well-written and
considered to publish in the BMC Gastroenterology.
assistant